Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Bioxodes meets enrollment milestone in Phase 2a intracerebral ...
Bioxodes announces positive Phase 2a interim data for BIOX-101 in ...
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX ...
Bioxodes meets first Phase 2a patient enrollment milestone | Nasirkhan ...
Bioxodes begins Phase 2a trial of BIOX-101 for intracerebral stroke ...
Bioxodes to present first-in-class drug candidate BIOX-101 for ...
Bioxodes reports phase 2a trial success for stroke treatment | Bio ...
A breakthrough for hemorrhagic stroke patients. | Bioxodes
Bioxodes Raises €5.5M to Advance Stroke Therapy BIOX-101
Bioxodes presents BIOX-101 clinical data showing breakthrough potential ...
Bioxodes presents positive final Phase 2a intracerebral hemorrhage ...
10. How Bioxodes is using tick saliva to create an ICH stroke treatment ...
Can Bioxodes end the dearth of haemorrhagic stroke drugs? | Bioxodes
Clinical Trials | Bioxodes | Bioxodes
Bioxodes announces the completion of the active phase of its First-in ...
Expert view on the need for hemorrhagic stroke care | Bioxodes
Bioxodes Reports Breakthrough Phase 2a Data for Stroke Drug
Bioxodes names new chairman, prepares pivotal stroke trial ...
Bioxodes reports phase 2a trial of therapeutic protein based on Ixodes ...
Bioxodes enrols first patient in Phase IIa intracerebral haemorrhage trial
Bioxodes secures new funds to reach early 2025 milestones and pursue ...
Contact us | Bioxodes | Bioxodes
In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into ...
BioBiz Buzz Podcast: How Bioxodes is using tick saliva to create an ICH ...
Bioxodes Series A Extension: €5.5M | Medical Device Navigator
Bioxodes SA (@bioxodes) / Twitter
Unique mechanism of action of BIOX-101 Bioxodes | Bioxodes
Bioxodes SA Phase 2a trial of factor XIa/XIIa inhibitor shows reduced ...
Bioxodes franchit une 1ère étape dans le recrutement de patients pour ...
Bioxodes presents latest developments at key international conferences ...
Stroke research progresses towards new frontier | Bioxodes
Bioxodes | | The Pharmaletter
Bioxodes - Gosselies, Belgium
Bioxodes recrute ses premiers patients pour le traitement des ...
Bioxodes Secures €12M in Series A Round Funding
Bioxodes plans to raise EUR 70m to bring to market itshemorrhagic ...
Bioxodes “The European Patent Office's intention to grant a patent for ...
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it ...
Can Bioxodes end the dearth of haemorrhagic stroke drugs? | pharmaphorum
Bioxodes lève 12 millions d’euros lors d’un tour de Série A | MyPharma ...
Thinking Outside The BIOX: Bioxodes Takes Novel Approach To ...
About us | Bioxodes | Bioxodes
Pipeline | Bioxodes | Bioxodes
Bonnes nouvelles pour la biotech carolo Bioxodes et son traitement des ...
Annual Biotech in Europe Forum | Bioxodes
Bioxodes closes €12 million in Series A funding round | Bioxodes
Bioxodes receives European Patent Office intention to grant patent ...
Bioxodes appoints Marc Dechamps as new CEO | Andrew Lloyd & Associates
Proud to announce that Bioxodes will be presenting at DON Elite Rooms ...
Bioxodes with management changes - European Biotechnology Magazine
Bioxodes Shares Pivotal Trial Design for BIOX-101 in ICH
Bioxodes presents at ISTH 2023 | Bioxodes
International Stroke Conference 2025 | Bioxodes
Bioxodes halts phase 2 stroke trial after successful interim review ...
Bioxodes - Sambrinvest
Bioxodes - WebKrea - Création site Internet Brabant Wallon
Bioxodes on LinkedIn: #bioeurope2023 #bioeuropefall #bioxodes # ...
Bioxodes Announces Positive Phase 2a Interim Data for BIOX-101
Bioxodes lève 5,5 millions d'euros dans le cadre d'une
Bioxodes nomme Marc Dechamps au poste de CEO | MyPharma Editions
Bioxodes lève 12 millions contre les hémorragies intracérébrales | L'Echo
European Stroke Organisation Conference – ESOC 2025 | Bioxodes
Mapping Rare Disease in 2026, report by Stifel | Bioxodes
Bioxodes raises €5.5 million Series A extension | Bioxodes
Brain Innovation Drays | Bioxodes
#thrombosis #neuroinflammation #hemorrhagic #stroke #sachs_elsf # ...
Anticoagulation With an Inhibitor of Factors XIa and XIIa During ...
Bioxodes’ haemorrhagic stroke hopeful to progress after Phase II success
Accurate Diagnosis And Enrollment Criteria Improve Intracerebral ...
Efficacy of a novel contact pathway inhibitor, Ir-CPI, in an ...
News – Cohesion Bureau
A轮融资1200万欧元，Bioxodes为2100万卒中患者研发无出血风险抗凝药物_腾讯新闻
#hemorrhagic #tick #aphasia #thrombectomy #voiceofstroke # ...
A轮融资1200万欧元，Bioxodes为2100万卒中患者研发无出血风险抗凝药物-动脉网
9家创新药公司完成新一轮融资！2家来自中国
Portfolio - SFPIM
#intracerebral #hemorrhage #ich #thrombosis #neuroinflammation #stroke ...
BioPharmaPulse
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ...
Imperative Care Launches Zoom 4S Catheter to Further Advance Company’s ...
#neuroinflammation #ich #hemorrhagic #stroke #neutrophils #strokecare # ...
Innovation Hall 2024 - Brain Innovation Days
